NCT06574503View on ClinicalTrials.gov

Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza

PHASE3RecruitingINTERVENTIONAL
Enrollment

748

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

July 30, 2027

Study Completion Date

December 30, 2027

Conditions
Influenza
Interventions
DRUG

GP681 40mg

2X20mg tablets taken orally

DRUG

GP681 Simulant

Placebo tablets matching GP681 40mg

Trial Locations (1)

Unknown

RECRUITING

Shulan (Hang Zhou) Hospital, Hanzhou

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY